Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Appital is an emerging financial market platform that will use digital profiling, unique algorithms and notifications to connect institutional demand and supply. With Appital, corporate and institutional companies within the equity capital markets space will have the opportunity to exchange illiquid equity without an investment bank or broker. Appital will also remove the dependence on email and phone, thereby ensuring efficiency and accessibility. The company is raising fund to built the Appital software, achieve FCA regulation, generate marketing material and gain contracts with partner settlement and KYC providers. Furthermore, the company will enhance the functionality of the software by leveraging its network to other products such as primary debt and primary equity deal flow.
days to go:
Expired
investment:
£349,060
Doc2UK is a specialist UK medical recruitment and candidate support platform. Based in London, the platform places qualified doctors in the National Health Scheme (NHS) roles around the United Kingdom. The British Medical Association (2018) reported that patient care is at risk due to a critical shortage of doctors across multiple medical disciplines. At present, the UK only has 24 medical schools to fill this gap, whilst India, in comparison, has 468 medical schools, with 68,000 doctors graduating each year. Moreover, uncertainty about the status of EU nationals after Brexit, changes to immigration policies, and the impact of changing language testing requirements for international nurses have made this crisis worse. This situation necessitates recruiting doctors from overseas an important endeavour. This is where Doc2UK aims to become a key player and ensure that lack of medical personnel doesn't disrupt any medical services. The company is seeking an investment of up to £300,000 which will be used to develop the platform with more features, expand the team, marketing and sales.
days to go:
Expired
investment:
Withheld
FinOptix is an innovative FinTech company that solves real business problems. FinOptix’s objective is to become a significant player in a rapidly growing FinTech market by developing systems that provide financial clarity to decision-makers. FinOptix has a well-established user base, as well as a sales pipeline that covers multiple geographies and sectors. Their verification and validation procedures applied during the development process and operational trials have led to engagement with commercial partners. With the proceeds, they will design an Evaluator for the future, apply AI techniques to solve complex problems, develop their skill set and framework and hire a team of data scientists based on the assessment.
days to go:
Expired
investment:
£125,000
The Studio enable members to achieve results through sustainable, structured training. The Studio offer a whole range of sessions such as group classes, one-to-one personal training, spinning and yoga.
days to go:
Expired
investment:
£30,564
Love2move has developed a platform to bridge the gap between sellers/ homeowners and the market. It functions as an internet estate agent working in collaboration with well- established estate agents with a physical office. This way Love2move provides its users the best of both traditional as well as online estate agents. With the help of online sales platform, the agents can list homes without much setup costs involved.
days to go:
Expired
investment:
£51,850
With new MiFID II regulations introduced in January, Hiddensee provides independent investment research mainly on forensic accounting and corporate governance. Analysts will search for inconsistencies and anomalies in the valuation of UK listed mid-cap and smaller companies and publish their reports to assist investors in deciding whether to buy or sell shares.
days to go:
Expired
investment:
£143,097
